Biology and genetics

Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Zang M et al. Cancer Lett. 2015 Jun 23. pii: S0304-3835(15)00403-6. doi: 10.1016/j.canlet.2015.06.011. [Epub ahead of print]. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Kandela I et al. Elife. 2015 Jun 25;4. doi: 10.7554/eLife.07072. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Riz I et…

Journal, Library, Management of Myeloma

Supportive care

Safety and efficacy of kyphoplasty in the treatment of tumoral disease of the spine. García-Maroto R et al. Rev Esp Cir Ortop Traumatol. 2015 Jun 19. pii: S1888-4415(15)00058-2. doi: 10.1016/j.recot.2015.05.003. [Epub ahead of print]. Risks and Benefits of Bisphosphonate Therapies. Reyes C er al. J Cell Biochem. 2015 Jun 20. doi: 10.1002/jcb.25266. [Epub ahead of print]. Adherence to analgesics for cancer…

Journal, Library, Myeloma Prognosis & Outcomes

General

Differentiated plasma cell myeloma presenting as a solitary spinal amyloidoma: A case report, possible pitfall and review to the literature. Brawanski N et al. Clin Neurol Neurosurg. 2015 Jun 10;137:1-4. doi: 10.1016/j.clineuro.2015.05.027. [Epub ahead of print]. Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma. Gormley NJ et al. Cytometry B Clin Cytom. 2015 Jun 23. doi: 10.1002/cyto.b.21268. [Epub ahead of…

Journal, Library

Complications of myeloma and its treatments

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Teh BW et al. Br J Haematol. 2015 Jun 24. doi: 10.1111/bjh.13532. [Epub ahead of print]. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Undas A et al. Blood Coagul Fibrinolysis. 2015 Jun 11. [Epub…

Journal, Library, Management of complications & side effects

Current treatments

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Obama K. Acta Haematol. 2015 Jun 11;134(4):229-230. [Epub ahead of print]/ Biosimilar filgrastim (Zarzio®) vs Lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with myeloma and lymphoma: A single center experience. Marchesi F et al. Leuk Lymphoma. 2015 Jun 23:1-12.…

Journal, Library

Diagnostic tests and prognostic indicators

Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM). Zacchino M et al. Eur Radiol. 2015 May 20. [Epub ahead of print]. Global hypomethylation in myeloma is associated with poor prognosis. Sive JI et al. Br J Haematol. 2015 May 26. doi: 10.1111/bjh.13506. [Epub ahead of print]. Circulating plasma cells in newly diagnosed symptomatic multiple…

Diagnosing and Monitoring Myeloma, Journal, Library

Related conditions

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Cibeira MT et al. Br J Haematol. 2015 May 14. doi: 10.1111/bjh.13500. [Epub ahead of print]. Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late? Ramirez GA et al. Intern Med. 2015;54(9):1119-23. doi: 10.2169/internalmedicine.54.3668. Epub 2015 May 1. Abnormal FISH…

Journal, Library

Emerging treatments

A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Benson DM Jr et al. Clin Cancer Res. 2015 May 21. pii: clincanres.0304.2015. [Epub ahead of print]. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Noonan KA et al. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.…

Journal, Library

Biology and genetics

Lenalidomide augments actin remodelling and lowers NK cell activation thresholds. Lagrue K et al. Blood. 2015 May 22. pii: blood-2015-01-625004. [Epub ahead of print]. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in Multiple Myeloma. Yousef S et al. Hum Vaccin Immunother. 2015 May 22:0. [Epub ahead of print]. MicroC3: an ex vivo…

Journal, Library, Management of Myeloma

Supportive care

Comparison of Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Single Level Vertebral Compression Fractures: A Meta-analysis of the Literature. Wang H et al. Pain Physician. 2015 May-Jun;18(3):209-22. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Diel IJ et al. Eur J Cancer. 2015 May 11. pii: S0959-8049(15)00373-1. doi: 10.1016/j.ejca.2015.04.017.…

Journal, Library, Myeloma Prognosis & Outcomes